Special ABA Section member price
This resource equips transactional health care attorneys to adequately advise clients on fraud-and-abuse risks unique to this submarket of the health care industry. It breaks down the full legal and regulatory context of: off-label marketing; antitrust, securities law, and other compliance violations; reimbursement; civil and regulatory liability under securities and antitrust laws; compliance and corporate governance issues; and more.<p> </p>
Main Volume Information
2007/899 pp. Hardcover with 2014 Cumulative Supplement/Order #ABAWEB2323/$266.25
Pharmaceutical Law: Regulation of Research, Development, and Marketing is the only resource available that provides expert commentary and authoritative insights into a comprehensive range of pharmaceutical law issues. In fact, no other single volume discusses these complex issues in so much detail and offers the information required by transactional health care attorneys to adequately advise clients on the opportunities—and the liabilities—in this industry. This treatise addresses the considerable fraud-and-abuse risks unique to this submarket of the health care industry; covers off-label marketing—selling a drug for a purpose other than its intended use; and explains and discusses other hot risks areas, including the potential for antitrust, securities law, and other compliance violations.
The Medicare Part D drug benefit, coupled with the confusing and cumbersome methodology used for reimbursement, has added pressures to the already strained Medicare budget, increasing regulatory scrutiny and creating traps for the unwary and uninformed. Other increasingly important areas—including reimbursement and regulation, civil and regulatory liability under the securities and antitrust laws, and compliance and corporate governance issues—also are receiving increased attention from regulators.
Pharmaceutical Law: Regulation of Research, Development, and Marketing is a reference attorneys will turn to time and again for answers and guidance in all areas of pharmaceutical law.
2014 Cumulative Supplement alone: ISBN 9781617465093/Order #ABAWEB2509/$195.00
The 2014 Cumulative Supplementincludes: extensive new discussion of the New Drug Application process; analysis of the FDA’s 2013 final guidance recommending risk-based approaches to clinical investigations monitoring by trial sponsors; Coverage of the Drug Quality and Security Act of 2013; review of DOJ 2013 and 2014 settlements in pharmaceutical cases; discussion of Anderson v. Peregrine Pharms., Inc., a securities class action for false and misleading statements about the effectiveness of an experimental drug; and other new developments.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).